EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Obeticholic Acid Therapy on Insulin Resistance and Metabolic Parameters in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)

Majid Almansouri iD, Hani Shalabi iD, Mohammed Karami iD, Omar Alharthy, Ali Kabli iD, Mohammad Khalil iD, Maan Alkhattabi iD, Dahlia Mirdad iD, Ahmed Alharthy iD, Ahmed Abduljabbar iD, Mohammed Wazzan iD, Hatim Alabsi und 3 weitere

International Journal of Hepatology · 2026-01 · 2026 (1)

DOI: 10.1155/ijh/3306359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hepatology, online erschienen am 06.08.2026. Verfasst von Majid Almansouri und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, kau.edu.sa. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction–associated steatotic liver disease (MASLD) is a common metabolic liver condition primarily managed through lifestyle modification. Obeticholic acid (OCA), a farnesoid X receptor agonist, has shown therapeutic benefits in steatohepatitis, yet its short‐term metabolic effects remain unclear. This study compared OCA plus lifestyle modification versus lifestyle intervention alone in adults with MASLD.

Methods

This quasi‐experimental study included 360 adults aged 18–60 years with ultrasound‐diagnosed MASLD and insulin resistance (HOMA − IR > 2.0). Patients with diabetes mellitus, viral hepatitis, cirrhosis, advanced fibrosis, ischemic heart disease or LDL − C > 160 mg/dL were excluded. Participants received either OCA (10 mg/day) plus standardised lifestyle modification or lifestyle intervention alone for 3 months. Anthropometric, biochemical and hepatic parameters were evaluated at baseline and follow‐up, with ANCOVA performed to adjust for baseline covariates.

Results

Baseline demographic and metabolic characteristics were comparable between groups. After 3 months, the OCA plus lifestyle group demonstrated significantly greater improvements in ALT (36.65 ± 20.57 vs. 48.19 ± 21.35 U/L; p < 0.001), fatty liver index (55.99 ± 12.60 vs. 63.08 ± 11.89; p < 0.001) and HEPAMET score (0.33 ± 0.13 vs. 0.41 ± 0.13; p < 0.001), along with a greater reduction in body weight (77.28 ± 12.07 kg vs. 80.19 ± 12.37 kg; p = 0.024). Postintervention HOMA‐IR was significantly lower with OCA plus lifestyle than lifestyle alone (2.46 ± 0.92 vs. 2.96 ± 1.06; mean difference 0.50; p < 0.001). LDL‐C increased significantly in the OCA group (139.50 ± 15.74 mg/dL vs. 131.96 ± 16.36 mg/dL; p < 0.001).

Conclusion

Over 3 months, OCA combined with lifestyle modification improved liver enzymes, steatosis and fibrosis‐related surrogate indices, and modestly reduced insulin resistance. Careful lipid monitoring is recommended, and longer term studies are required to clarify the overall metabolic and cardiovascular implications.

Schlagwörter

Stichwörter der Autor:innen

insulin resistancemetabolic dysfunction–associated steatotic liver diseaseobeticholic acid

Autor:innen und Institutionen

  • Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, kau.edu.sa.
  • Department of Internal Medicine, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia, uj.edu.sa.
  • Department of Clinical Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, kau.edu.sa.
  • Department of Internal Medicine, Faculty of Medicine, University of Taibah, Madina, Saudi Arabia, taibahu.edu.sa.
  • Department of Physiology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia, kau.edu.sa.
  • Department of Radiology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, kau.edu.sa.

ORCID-Profile: Majid Almansouri, Hani Shalabi, Mohammed Karami, Ali Kabli, Mohammad Khalil, Maan Alkhattabi, Dahlia Mirdad, Ahmed Alharthy, Ahmed Abduljabbar, Mohammed Wazzan, Siti S Maidin, Humaira Waseem, Amber Hassan

Zitieren

APA

Almansouri, M., Shalabi, H., Karami, M., Alharthy, O., Kabli, A., Khalil, M., Alkhattabi, M., Mirdad, D., Alharthy, A., Abduljabbar, A., Wazzan, M., Alabsi, H., Maidin, S. S., Waseem, H., & Hassan, A. (2026). Impact of Obeticholic Acid Therapy on Insulin Resistance and Metabolic Parameters in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD). International Journal of Hepatology, 2026(1). https://doi.org/10.1155/ijh/3306359

Vancouver

Almansouri M, Shalabi H, Karami M, Alharthy O, Kabli A, Khalil M, et al. Impact of Obeticholic Acid Therapy on Insulin Resistance and Metabolic Parameters in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD). International Journal of Hepatology. 2026;2026(1). doi:10.1155/ijh/3306359

BibTeX
@article{Almansouri2026,
  author = {Almansouri, Majid and Shalabi, Hani and Karami, Mohammed and Alharthy, Omar and Kabli, Ali and Khalil, Mohammad and Alkhattabi, Maan and Mirdad, Dahlia and Alharthy, Ahmed and Abduljabbar, Ahmed and Wazzan, Mohammed and Alabsi, Hatim and Maidin, Siti S and Waseem, Humaira and Hassan, Amber},
  title = {Impact of Obeticholic Acid Therapy on Insulin Resistance and Metabolic Parameters in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)},
  journal = {International Journal of Hepatology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ijh/3306359}
}
Kostenlos starten →